Takeda inches closer to take over ShireEuropost
Takeda Pharmaceutical announced onTuesday that it has received US approval for its $62bn acquisition of London-listed Shire. The Japanese company is still awaiting approval from regulators in China and the EU, as well as from shareholders of both firms.
CEO Christophe Weber is trying to persuade investors about the deal's cost-saving merits, but concerns of the financial burden the combined company will carry has already influence Takeda's stock price. If finalised, the deal would help the Japanese enter the list of global top 10 drugmakers.